Macrocyclic Compounds, SRC MET Inhibitor, Cancer Treatment

Tue, 21 Apr 2026 12:42:56 +0000
Intellectual Property

USPTO granted patent US12606571B2 to Turning Point Therapeutics, Inc. for macrocyclic compounds that inhibit SRC and MET and/or CSF1R, pharmaceutical compositions thereof, and methods of using such compounds to treat cancer. The patent contains 9 claims and was granted on April 21, 2026.